158 related articles for article (PubMed ID: 34780851)
1. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.
Fisk JN; Mahal AR; Dornburg A; Gaffney SG; Aneja S; Contessa JN; Rimm D; Yu JB; Townsend JP
Cancer Lett; 2022 Feb; 526():346-351. PubMed ID: 34780851
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Markóczy Z; Sárosi V; Kudaba I; Gálffy G; Turay ÜY; Demirkazik A; Purkalne G; Somfay A; Pápai-Székely Z; Rásó E; Ostoros G
BMC Cancer; 2018 May; 18(1):598. PubMed ID: 29801465
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Wu YL; Lee V; Liam CK; Lu S; Park K; Srimuninnimit V; Wang J; Zhou C; Appius A; Button P; Hooper G; Palma JF; Schulze K; Scudder S; Shames DS; Yin AY; Zhang G; Mok T;
Lung Cancer; 2018 Dec; 126():1-8. PubMed ID: 30527172
[TBL] [Abstract][Full Text] [Related]
4. Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
Kim EY; Kim A; Lee G; Lee H; Chang YS
BMC Cancer; 2018 Dec; 18(1):1221. PubMed ID: 30522449
[TBL] [Abstract][Full Text] [Related]
5. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Cheng C; Zhao Y; Schaafsma E; Weng YL; Amos C
Int J Cancer; 2020 Nov; 147(9):2621-2633. PubMed ID: 32406930
[TBL] [Abstract][Full Text] [Related]
6. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.
Grassberger C; McClatchy D; Geng C; Kamran SC; Fintelmann F; Maruvka YE; Piotrowska Z; Willers H; Sequist LV; Hata AN; Paganetti H
Cancer Res; 2019 Jul; 79(14):3776-3788. PubMed ID: 31113818
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
[TBL] [Abstract][Full Text] [Related]
8. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
9. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
11. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Yang H; He D; Wang F; Deng Q; Xie Z
Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218
[TBL] [Abstract][Full Text] [Related]
12. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
[TBL] [Abstract][Full Text] [Related]
13. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
14. Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma.
Veccia A; Girlando S; Dipasquale M; Kinspergher S; Barbareschi M; Caffo O
J BUON; 2020; 25(2):848-854. PubMed ID: 32521877
[TBL] [Abstract][Full Text] [Related]
15. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
16. Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.
Jing W; Wang H; Kong L; Yu J; Zhu H
Cancer Biol Ther; 2018; 19(12):1073-1077. PubMed ID: 30067451
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
Sorensen BS; Wu L; Wei W; Tsai J; Weber B; Nexo E; Meldgaard P
Cancer; 2014 Dec; 120(24):3896-901. PubMed ID: 25103305
[TBL] [Abstract][Full Text] [Related]
18. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
19. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
20. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
